What a Buprenorphine Dispensing Rate Actually Measures
To understand whether more buprenorphine prescribing becomes reliable treatment access, start with the number that is easiest to see: prescriptions dispensed. This chapter examines what the CDC's dispensing-rate map can reveal about U.S. buprenorphine activity, how its rate is constructed, and where the measure stops. The practical payoff is simple: readers can use the map as evidence of geographic dispensing patterns without mistaking it for a count of patients who received uninterrupted care.
The CDC map shows activity, not a treatment guarantee
The CDC reports that the national buprenorphine dispensing rate remained relatively stable from 2019 through 2024. In 2024, the rate was 4.5 buprenorphine prescriptions per 100 persons, representing more than 15 million prescriptions. The page also reports wide differences among states. West Virginia's listed rate was 24.9 prescriptions per 100 persons, while Vermont, Kentucky, and Maine were also among the states with the highest rates. At the low end, Iowa's listed rate was 1.2, followed by Texas at 1.4, California at 1.6, and Hawaii at 1.7.
Those figures establish an important population-level pattern: retail dispensing activity varies widely across the country. They do not establish a ranking of treatment quality, prescribing competence, or patient experience. A state with a higher rate may have more people receiving medication, more refills per patient, greater recorded retail use, stronger pharmacy participation, or several of those conditions at once. A lower rate may reflect limited treatment capacity, barriers in obtaining medication, different patterns of care, or a mixture of factors. The map shows the difference; it does not identify the mechanism behind it.
The phrase “4.5 prescriptions per 100 persons per year” also needs to be read carefully. The unit is prescriptions, not people. One person may account for multiple prescriptions because the measure includes new and refilled prescriptions. Another person may have a prescription issued but never successfully fill it; that failed transaction would not become a completed retail dispensing event in the same way. The annual rate therefore says that a large amount of prescription activity was recorded relative to the resident population. It does not say that 4.5 people out of every 100 began treatment, completed a course, or had no interruption.
That distinction is not a technical quibble. For a medication used to treat opioid use disorder, timing can be part of access. If a patient is told that a prescription exists but must wait while a pharmacy orders it, call the prescriber, resolve coverage, or locate another pharmacy, the annual state total may eventually record a dispensing event. It will not show the days spent without medication. A measure can be accurate about what it counts and still be incomplete about what a patient experiences.
State comparisons need the same discipline. Consider two states at opposite ends of the CDC's listed range. The comparison is useful for asking why retail dispensing activity differs. It is not enough to conclude that clinicians in the higher-rate state prescribe more effectively or that patients there have fewer barriers. State rates combine population, prescribing, pharmacy, payment, and refill conditions. They may also reflect differences in the kinds of care people use. The source does not connect the state values to a prescriber census or to a patient-level measure of successful filling.
The reported national stability needs careful wording as well. A rate that remains relatively stable does not prove that nothing changed inside the system. More prescribing, changing patient need, different refill patterns, or new pharmacy constraints could move in opposite directions and leave the aggregate near the same level. The map reports the observed annual pattern, not the reasons behind its persistence. It also does not tell us whether a policy change widened access for one group while another group continued to face a pharmacy barrier. A stable average can contain local improvement and local failure at the same time.
The map is thus best understood as a signal about the amount and distribution of dispensing activity. It is an important signal because a system cannot provide medication if no prescriptions are dispensed at all. But it is an upstream signal in the access chain. To understand reliable treatment, we need to ask what was counted before the rate was calculated and what happened after a clinician wrote an order.
How the rate is built—and where the patient disappears
The CDC describes the map as showing the estimated rate of retail pharmacy-dispensed buprenorphine prescriptions per 100 persons per year for each of the 50 states and the District of Columbia. The data come from IQVIA Xponent for 2019 through 2024. That database uses a sample of approximately 54,600 retail, non-hospital pharmacies that dispense nearly 94% of all retail prescriptions in the United States. The source says the sample includes prescriptions paid through commercial insurance, Medicaid, Medicare, cash or its equivalent, and other third-party coverage.
This is a substantial data source, but “nearly 94%” is not the same as every prescription in every setting. The map describes a projection from the sample, not a direct headcount of every transaction. The numerator is the projected total number of buprenorphine prescriptions dispensed during a year at the state, county, or national level. The denominator is the annual resident population obtained from the U.S. Census Bureau. Dividing one by the other produces a comparable annual rate, not a patient registry.
The construction makes sense for surveillance. A national public-health agency needs a consistent way to observe broad patterns across places and years. A population denominator helps distinguish a state with a larger population from one with more dispensing relative to its size. A sample that covers most retail prescriptions can provide a useful estimate without requiring every pharmacy to submit a separate report. These design choices improve the map's ability to describe retail dispensing activity.
They also mean that the estimate should be interpreted as an estimate of a defined channel, not as a literal inventory of all treatment. Sampling coverage, projection, and the choice of denominator are strengths for comparison, but they also impose assumptions. The measure is most informative when the question is “How much retail dispensing activity was estimated relative to the resident population?” It is less informative when the question is “How many people could obtain their next dose today?” The second question needs data recorded at a different time and level.
They also establish the map's limits. First, the map is about retail, non-hospital pharmacies. It does not include mail-order prescriptions. A patient who receives buprenorphine through a delivery service is outside that channel even if the treatment is reliable. That omission does not mean delivery is more common or more effective; it means the map cannot be used to describe every route by which medication reaches a patient.
Second, the page excludes Belbuca and Butrans, formulations commonly prescribed for pain. The map is therefore not a measure of every use of every buprenorphine formulation. This exclusion helps align the data with the OUD-focused question, but it also means the figure must not be casually described as all buprenorphine prescribing.
Third, geographic assignment is based on the location of the prescriber. That choice can differ from the patient's residence, the pharmacy where the prescription is filled, and the route by which medication is delivered. A prescription from a clinician in one place may be filled by a patient somewhere else. In the context of telemedicine, the distinction becomes especially important: the map's geography does not tell us how far the patient traveled, how close the pharmacy was, or whether a remote prescriber caused a particular fill problem.
Finally, the map contains annual totals. It is not designed to show whether a pharmacy had inventory on a specific day, whether an insurer required prior authorization, whether a pharmacist questioned a telemedicine prescription, or whether a patient had to go without medication while the issue was resolved. Those are transaction-level and continuity-level questions. They require different data.
The rate can be represented as a compact measurement pipeline:
This diagram does not mean that the CDC ignores patients. It shows that the map answers a different question from a patient survey. It starts with a pharmacy sample, estimates the number of retail prescriptions dispensed, assigns geography through the prescriber, and compares the result with resident population. The patient becomes visible indirectly through population and prescription activity, not through a record of waiting time or treatment continuity.
Three mistakes the rate cannot support
The first mistake is to read a state rate as a prescriber count. The CDC map does not report how many clinicians prescribe buprenorphine, how many prescriptions each clinician writes, or how many patients each clinician serves. Its geographic assignment is based on prescriber location, but that is not the same as measuring the prescriber workforce. A state can have a particular dispensing rate without the map telling us whether it came from many clinicians writing fewer prescriptions or fewer clinicians writing more.
The second mistake is to read dispensing as availability. A prescription recorded in an annual total tells us that dispensing occurred; it does not tell us how easily the next prescription could be obtained. The measure has no field for a stockout, an order limit, a rejected claim, a pharmacist's hesitation, a trip to another pharmacy, or days without medication. These omissions are not evidence that those events did not happen. They are evidence that this measure was not designed to observe them.
The third mistake is to read a state difference as a causal explanation. The map can show that dispensing activity is higher in one state than another, but it cannot establish that the difference was caused by prescriber availability, telemedicine rules, pharmacy practice, insurance design, or any single factor. A causal claim would require a design that compares relevant groups or changes over time while accounting for alternative explanations. The CDC page supplies surveillance evidence, not that causal comparison.
A simple hypothetical makes the distinction concrete. Suppose two states each record the same annual number of prescriptions per 100 residents. In the first, most patients refill on time through local pharmacies. In the second, patients often call several pharmacies before finding stock, but eventually enough prescriptions are dispensed to produce the same annual total. The map would treat the annual totals as equivalent even though the reliability of treatment differs. The example is not a claim about either state; it shows why an annual aggregate cannot answer a timing question.
The reverse is also possible. A state may increase dispensing activity because established patients receive more refills, while the number of newly treated patients changes little. Or dispensing may rise because more prescriptions are written and filled in retail pharmacies, while a separate group still faces insurance or inventory barriers. The same headline can coexist with different patient experiences. To move from activity to access, the analysis must add a measure of the transaction and its duration.
That is the map's value when its boundary is respected. It tells us that dispensing is large enough and uneven enough to deserve attention. It can reveal where surveillance should look more closely and whether broad patterns change across years. It cannot tell us whether the pharmacy can complete a particular order before a patient runs out. For that, a fuller access picture would pair the annual map with measures such as time-to-fill, inventory or ordering problems, rejected or delayed claims, patient residence and travel burden, days without medication, and treatment continuity. Those measures are complementary, not replacements for the map.
The next step is therefore not to discard the CDC measure, but to place it in the right layer. It describes annual retail dispensing activity. The unresolved question is what happens between a prescription being issued and a patient receiving medication: whether stock, ordering, insurance, professional judgment, or distance turns potential access into a delay. That is where the pharmacy becomes a gate.